Effectiveness of raloxifene and alendronate combination versus calcium and vitamin D usage: Effects on bone mineral density Raloksifen ve alendronat kombinasyonunun kalsiyum ve D vitamini kullanimina karşi etkinliǧi: Kemik mineral yoǧunluǧu üzerindeki etkiler
Journal of the Turkish German Gynecology Association, cilt.6, sa.2, ss.139-145, 2005 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 6 Sayı: 2
- Basım Tarihi: 2005
- Dergi Adı: Journal of the Turkish German Gynecology Association
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.139-145
- Anahtar Kelimeler: Alendronate, Bone mineral density, Osteoporosis, Raloxifene, Treatment
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Objective: The primary objective is to evaluate the effects of alendronate and raloxifene, either alone or in combination, compared with calcium and vitamin D, on lumbar spine and femoral neck bone mineral density (BMD). Materials and Methods: In this prospective, randomized, double blinded study, with a duration of 1 year, we assessed the effects of combined alendronate and raloxifene in 120 natural or surgical postmenopausal women with osteopenia and osteoporosis (femoral neck or lumbar spine BMD T-score less then -1 SD). Women were randomly assigned to one of the following groups: Group 1 received 10 mg/day alendronate + 600 mg/day calcium and 400 IU/day vitamin D, group 2 received 60 mg/day raloxifene + 600 mg/day calcium and 400 IU/day vitamin D, group 3 received 10 mg/day alendronate and 60 mg/day raloxifene combined + 600 mg/day calcium and 400 IU/day vitamin D and group 4 received only 600 mg/day calcium and 400 IU/day vitamin D. At baseline and 12th months, BMD was measured by dual x-ray absorptiometry at the lumbar spine (L1-4) and femoral neck. All the results were compared to each other. Student's paired t-test and ANOVA model were used for statistical analysis. P values less than 0.05 were considered as statistically significant. Results: Mean lumbar spine BMD increased by 3.7%, 2.5% and 6.3% from baseline with alendronate, raloxifene and combination therapy, respectively after 12 months in postmenopausal women (P<0.05). The BMD increment at femoral neck was 2.5%, 1.2% and 3.79% respectively. The effects of alendronate alone and in combination with raloxifene on the lumbar spine and femoral neck BMD were greater than those observed with raloxifene alone. Conclusions: In postmenopausal women with osteoporosis or osteopenia, the combination of alendronate/raloxifene was superior to either therapy alone in terms of BMD increment.